About Guanine nucleotide-binding protein G(t) subunit alpha-1
Guanine nucleotide-binding protein G(t) subunit alpha-1 (GNAT1) is a protein
from Homo sapiens identified by UniProt accession
P11488, 350 residues long.
MolForge cross-references it against 0 known binders and
75 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein G(t) subunit alpha-1 |
| UniProt accession | P11488 |
| Gene | GNAT1 |
| Organism | Homo sapiens |
| Length | 350 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (75)
Diseases linked to this target (Open Targets).
- congenital stationary night blindness · score 0.64
- retinitis pigmentosa · score 0.45
- Cone rod dystrophy · score 0.37
- neurodegenerative disease · score 0.31
- Retinal dystrophy · score 0.30
- ovarian cancer · score 0.25
- lung adenocarcinoma · score 0.23
- head and neck squamous cell carcinoma · score 0.23
- gastric adenocarcinoma · score 0.23
- urinary bladder cancer · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P11488-F1 | alphafold | PREDICTED | 94.21 | — |
Amino-acid sequence (350 residues)
MGAGASAEEK HSRELEKKLK EDAEKDARTV KLLLLGAGES GKSTIVKQMK IIHQDGYSLE ECLEFIAIIY GNTLQSILAI VRAMTTLNIQ YGDSARQDDA RKLMHMADTI EEGTMPKEMS DIIQRLWKDS GIQACFERAS EYQLNDSAGY YLSDLERLVT PGYVPTEQDV LRSRVKTTGI IETQFSFKDL NFRMFDVGGQ RSERKKWIHC FEGVTCIIFI AALSAYDMVL VEDDEVNRMH ESLHLFNSIC NHRYFATTSI VLFLNKKDVF FEKIKKAHLS ICFPDYDGPN TYEDAGNYIK VQFLELNMRR DVKEIYSHMT CATDTQNVKF VFDAVTDIII KENLKDCGLF
Explore Guanine nucleotide-binding protein G(t) subunit alpha-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets